Core Viewpoint - The announcement indicates that Harbin Zhenbao Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Zhenbao Island (603567), has received approval from the National Medical Products Administration for the transfer of marketing authorization for ten drugs from Anhui Jiuzhou Fangyuan Pharmaceutical Co., Ltd. to Harbin Zhenbao Pharmaceutical Co., Ltd. This change is not expected to have a significant impact on the company's current operating performance [1]. Group 1 - The approval includes the transfer of marketing authorization for ten drugs, which are Olanzapine Tablets, Apixaban Tablets, Escitalopram Oxalate Tablets, Desloratadine Tablets, Voriconazole Tablets, Mecobalamin Tablets, Rivaroxaban Tablets, Valsartan Tablets, and Donepezil Hydrochloride Tablets [1]. - The change in marketing authorization holders is a strategic move for Harbin Zhenbao Pharmaceutical Co., Ltd. to consolidate its product portfolio [1]. - The company emphasizes that this regulatory approval will not materially affect its current financial performance [1].